Related content

Preattentional and attentional cognitive deficits as targets for treating schizophrenia

By Braff David   Light Gregory  

Psychopharmacology, Vol. 174, Iss. 1, 2004-06 ,pp. : 75-85

Springer Publishing Company

Access to resources Recommend Favorite

GABA Targets for the Treatment of Cognitive Dysfunction in Schizophrenia

By  

Current Neuropharmacology, Vol. 3, Iss. 1, 2005-01 ,pp. : 45-62

Bentham Science Publishers

Access to resources Recommend Favorite

The Role of 5 GABAA Receptor Agonists in the Treatment of Cognitive Deficits in Schizophrenia

By  

Current Pharmaceutical Design, Vol. 20, Iss. 31, 2014-09 ,pp. : 5069-5076

Bentham Science Publishers

Access to resources Recommend Favorite

Treatment of Cognitive Deficits Associated with Schizophrenia: Potential Role of Catechol-O-Methyltransferase Inhibitors

By Apud José A.   Weinberger Daniel R.  

CNS Drugs, Vol. 21, Iss. 7, 2007-01 ,pp. : 535-557

Adis International

Access to resources Recommend Favorite

Nicotinic Receptors and the Treatment of Attentional and Cognitive Deficits in Neuropsychiatric Disorders: Focus on the 7 Nicotinic Acetylcholine Receptor as a Promising Drug Target for Schizophrenia

By  

Central Nervous System Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Central Nervous System Agents), Vol. 7, Iss. 4, 2007-12 ,pp. : 269-288

Bentham Science Publishers

Access to resources Recommend Favorite